Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma

被引：2
|
作者：
Wasko, Urszula N.
Sastra, Stephen A.
Palermo, Carmine F.
Wildes, David
Singh, Mallika
Olive, Kenneth P.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1725
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1725
引用
收藏
页数：2
相关论文
共 8 条
  • [1] Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma.
    Wasko, Urszula N.
    Sastra, Stephen A.
    Palermo, Carmine F.
    Wildes, David
    Singh, Mallika
    Olive, Kenneth P.
    CANCER RESEARCH, 2022, 82 (22) : 105 - 106
  • [2] Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors
    Wasko, Urszula N.
    Jiang, Jingjing
    Wang, Yingyun
    Tomassoni, Lorenzo
    Jiang, Lingyan
    Menard, Marie
    Curiel-Garcia, Alvaro
    Dalton, Tanner C.
    Orlen, Margo
    Edwards, Cole
    Stalnecker, Clint
    Dilly, Julien
    Chang, Stephanie
    Sastra, Stephen A.
    Palermo, Carmine F.
    Baslan, Timour
    Tian, Sha
    Holderfield, Matthew
    Quintana, Elsa
    Wang, Zhengping
    Smith, Jacqueline A.
    Califano, Andrea
    Wildes, David
    Aguirre, Andrew J.
    Vonderheide, Robert H.
    Stanger, Ben Z.
    Lowe, Scott W.
    Der, Channing J.
    Singh, Mallika
    Olive, Kenneth P.
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
    Gustafson, W. Clay
    Wildes, David
    Rice, Meghan A.
    Lee, Bianca J.
    Jiang, Jingjing
    Wang, Zhengping
    Chang, Stephanie
    Flagella, Mike
    Mu, Yunming
    Dinglasan, Nuntana
    Nasholm, Nicole
    Evans, James W.
    Seamon, Kyle
    Cregg, Jim
    Bermingham, Alun
    Freilich, Rebecca
    Gill, Adrian L.
    Koltun, Elena
    Smith, Jacqueline A.
    Singh, Mallika
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
    Yan, Sau-Chi Betty
    Um, Suzane L.
    Peek, Victoria L.
    Thobe, Megan N.
    Credille, Kelly M.
    Stephens, Jennifer R.
    Manro, Jason R.
    Ballard, Darryl W.
    Baker, Jessica A.
    Cook, Joel D.
    Konicek, Bruce W.
    Graff, Jeremy R.
    Holzer, Timothy R.
    Walgren, Richard A.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
    Bandi, Dhana Sekhar Reddy
    Nagaraju, Ganji Purnachandra
    Sarvesh, Sujith
    Carstens, Julienne L.
    Foote, Jeremy B.
    Graff, Emily C.
    Fang, Yu-Hua D.
    Keeton, Adam B.
    Chen, Xi
    Valiyaveettil, Jacob
    Berry, Kristy L.
    Bae, Sejong
    Akce, Mehmet
    Gorman, Greg
    Yoon, Karina J.
    Manne, Upender
    Boyd, Michael R.
    Buchsbaum, Donald J.
    Azmi, Asfar S.
    Maxuitenko, Yulia Y.
    Piazza, Gary A.
    El-Rayes, Bassel F.
    MOLECULAR CANCER, 2025, 24 (01)
  • [6] Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma
    Yang, Wei
    Meng, Lingwei
    Chen, Kai
    Tian, Chenyu
    Peng, Bing
    Zhong, Lei
    Zhang, Chunhui
    Yang, Xin
    Zou, Jun
    Yang, Shengyong
    Li, Linli
    CANCER SCIENCE, 2019, 110 (04) : 1408 - 1419
  • [7] Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma
    Maxuitenko, Yulia Y.
    Foote, Jeremy B.
    Keeton, Adam B.
    Chen, Xi
    Berry, Kristy
    Fadlalla, Khalda
    Valiyaveettil, Jacob
    Huang, Chung-Hui
    Moore, Austin M.
    Graff, Emily C.
    Nagaraju, Ganji P.
    Carstens, Julienne L.
    El-Rayes, Bassel F.
    Buchsbaum, Donald J.
    Piazza, Gary A.
    CANCER RESEARCH, 2023, 83 (08)
  • [8] The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma
    Miknyoczki, SJ
    Chang, H
    Klein-Szanto, A
    Dionne, CA
    Ruggeri, BA
    CLINICAL CANCER RESEARCH, 1999, 5 (08) : 2205 - 2212
1